ClinicalTrials.gg
Active, not recruitingNCT05243797MajesTEC-4Updated Nov 10, 2026

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

A Phase 3 interventional study of Teclistamab and Lenalidomide in Multiple Myeloma, sponsored by European Myeloma Network B.V.. Active, not recruiting at 201 sites in 25 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by European Myeloma Network B.V. · Phase 3, Interventional, and Treatment

How we know

Updated Nov 10, 2026Now Active, not recruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,594
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies testing teclistamab in Multiple Myeloma — 22 open to participants now, 32 under way, 9 of them phase 3. teclistamab · Multiple Myeloma.

Planned enrollment
Largest of 33
1,594 · median 80
Started
2022
with 4 others
Phase 3
8 of 33
4 open now
Primary completion
2028-04
later than 15 of 31 live
Registered
3rd of 33
by date
Lead sponsor
2 of 33
European Myeloma Network B.V.

Among the 33 studies testing teclistamab in Multiple Myeloma, this one has the largest planned enrollment, is one of 5 that started in 2022, is one of 8 in phase 3, reaches primary completion later than 15 of the 31 other live ones, and was the 3rd registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

22 of the 33 studies testing teclistamab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About teclistamab

teclistamab: first FDA approval 2022 (TECVAYLI), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies testing teclistamab in Multiple Myeloma, or all of them as a file.
02

Study summary

This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Maintenance
  • Teclistamab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have a new diagnosis of multiple myeloma according to IMWG criteria and have received induction +/- consolidation.
  • Must have received only one and achieved at least a partial response (≥PR) as per IMWG 2016 response criteria (Kumar 2016) without evidence of progression at the time of first treatment dose.
  • Must not be intolerant to the starting dose of lenalidomide.
  • Must not have received any maintenance therapy.
  • Have an performance status score of 0, 1, or 2 at screening and immediately prior to the start of administration of study treatment
  • Have clinical laboratory values within prespecified range.

Exclusion criteria

Exclusion Criteria:

  • Received any prior BCMA-directed therapy.
  • Any previous therapy with an immune cell redirecting agent or gene modified adoptive cell therapy (eg, chimeric antigen receptor modified T cells, NK cells).
  • Discontinued treatment due to any AE related to lenalidomide as determined by the investigator.
  • Progressed on multiple myeloma therapy at any time prior to screening.
  • Received a cumulative dose of equivalent to ≥140 mg of prednisone within the 14 days prior to first treatment dose.
  • Received a live, attenuated vaccine within 4 weeks before first treatment dose. Non- or non-replicating authorized for emergency use (eg. COVID-19) are allowed.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,594 participants (estimated)

Study arms

  • Experimental
    Arm A: Teclistamab-Lenalidomide (Tec-Len)

    Teclistamab will be administered via a subcutaneous injection (SC)

    Drug: Teclistamab · Drug: Lenalidomide

  • Active comparator
    Arm B Lenalidomide Alone (Len)

    Lenalidomide orally.

    Drug: Lenalidomide

  • Experimental
    Arm C Teclistamab-Alone (Tec)

    Teclistamab will be administered via a subcutaneous injection (SC)

    Drug: Teclistamab

Interventions

  • Teclistamab will be administered via a subcutaneous injection (SC)

    Also known as: JNJ-64007957

  • Lenalidomide will be administered orally

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS is defined as the time from the date of randomization to the date of disease progression (as assessed by IMWG criteria) or death due to any cause, whichever occurs first.

    Time frame: from randomization to the date of disease progression or death (approximately up to 8 years)

  2. Minimal Residual Disease (MRD)-negative Complete Response (CR)

    12-month MRD-negative CR is defined as participants who achieve MRD-negative status at 12 months, as determined by next-generation flow cytometry (NGF) with sensitivity of 10\^-5, prior to progressive disease or subsequent anti-myeloma therapy, whichever is earlier, and who also achieve CR of better, according to IMWG criteria.

    Time frame: at month 12

Secondary outcomes

  1. Comparison of efficacy

    Efficacy, assessed by rate of CR or better, MRD negative CR, sustained MRD negativity, CR and MRD negative conversion PFS after next line of therapy (PFS2), time to next treatment (TTNT), OS and also safety, PK and immunogenicity

    Time frame: from randomization to the date of disease progression or death (approximately up to 8 years)

  2. Overall Survival (OS)

    Overall Survival (OS), measured from the date of from randomization to the date the subject's death

    Time frame: from the date of from randomization to the date the subject's death, assessed up to 8 years]

  3. Change in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core module (EORTC QLQ-C30) score and the difference between-treatment arms

    The EORTC QLQ-C30 is a 30-item questionnaire containing both single and multi-item measures. These include five functional scales (Physical, Role, Cognitive, Emotional, and Social Functioning), three symptom scales (Fatigue, Pain, and Nausea/Vomiting), a Global Health Status/ Quality-of-Life (QoL) scale, and six single items (Constipation, Diarrhea, Insomnia, Dyspnea, Appetite Loss, and Financial Difficulties). The scores ranges from 0-100, a high score for functional scales and for Global Health Status/QoL represent better functioning ability or Health-Related Quality-of-Life (HRQoL), whereas a high score for symptom scales and single items represents significant symptomatology.

    Time frame: baseline up to 8 years

  4. EQ-5D-5L health utility values and the difference between-treatment arms

    The EQ-5D-5L is a 5 item questionnaire that assesses 5 domains including mobility, self care, usual activities, pain/discomfort, and anxiety/depression plus a visual analog scale rating "health today"

    Time frame: baseline up to 8 years

  5. MySIm-Q Symptom and Impacts in Patients With Multiple Myeloma and the difference between treatment arms

    The MySIm-Q is a disease-specific PRO assessment complementary to the EORTC-QLQ-C30. It includes 17 items resulting in a symptom subscale and an impact subscale. The recall period is the "past 7 days", and responses are reported on a 5-point verbal rating scale.

    Time frame: baseline up to 8 years

  6. PRO-CTCAE to evaluate symptomatic toxicities by self-report and the difference between treatment arms

    The PRO-CTCAE Measurement System characterizes the frequency, severity, interference, and presence/absence of symptomatic toxicities. The PRO-CTCAE Item Library includes 124 items representing 78 symptomatic toxicities drawn from the CTCAE

    Time frame: baseline up to week 24

  7. PGIS to evaluate the patient global impression of severity of the Multiple Myeloma and the difference between treatment arms

    PGIS is a 1 item questionnaire that evaluates patients' health and assesses if there has been an improvement or decline in clinical status

    Time frame: baseline up to 8 years

07

Study locations

201 sites

Showing the first 100 of 201 sites across 25 countries. Choose a country and city above to see the rest.

08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Apr 2028, 67 months after the start.

Of 72 non-industry phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 87 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 108. This study's planned 67 months is below that.

Counting every sponsor, half of 181 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2022
First posted
Feb 17, 2022
StartActual
Sep 8, 2022
Primary completionEst.
Apr 2028
CompletionEst.
Apr 2032
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 10, 2026
Sites
11 sites removed. 6 sites changed recruiting status (4 now recruiting, 2 now withdrawn)
Show 6 sites
  • UCLA Medical Center · Los Angeles, United StatesNot yet recruiting→Recruiting
  • University of Chicago · Chicago, United StatesNot yet recruiting→Recruiting
  • Henry Ford St. John Hospital · Grosse Pointe Woods, United StatesNot yet recruiting→Withdrawn
  • East Carolina University · Greenville, United StatesNot yet recruiting→Recruiting
  • Penn Medicine Lancaster General · Lancaster, United StatesNot yet recruiting→Recruiting
  • UPMC Hillman Cancer Center · Pittsburgh, United StatesNot yet recruiting→Withdrawn
Show 11 removed
  • Henry Ford St. John Hospital · Grosse Pointe Woods, United States
  • Dartmouth-Hitchcock Medical Center · Lebanon, United States
  • UPMC Hillman Cancer Center · Pittsburgh, United States
  • Grupo Oncoclínicas Pesquisa Clínica · São Paulo, Brazil
  • Hospital Paulistano, Centro de Pesquisa Clinica R. Martiniano de Carvalho · São Paulo, Brazil
  • UOC Oncoematologia, Ospedale Policlinico Federico II · Naples, Italy
  • CCAB Centro Clinico Academico Braga Associacao · Braga, Portugal
  • Instituto Portugues De Oncologia De Lisboa Francisco Gentil E.P.E. · Lisbon, Portugal
  • Instituto Portugues De Oncologia Do Porto Francisco Gentil E.P.E. · Porto, Portugal
  • Sao Joao University Hospital Center · Porto, Portugal
  • Unidade Local De Saude De Gaia/Espinho E.P.E. · Porto, Portugal
across 2 updates, Oct 7, 2026 – Nov 10, 2026
Site contacts
Changed at 5 sites. See the sites
Show 5 sites
  • Henry Ford St. John Hospital · Grosse Pointe Woods, United StatesContact removed (no phone or email listed)
  • UPMC Hillman Cancer Center · Pittsburgh, United StatesContact removed (no phone or email listed)
  • Barwon Health University Hospital Geelong Andrew Love Cancer Centre · Geelong, AustraliaContact person changed (no phone or email listed)
  • Calvary Mater Hospital · Newcastle, AustraliaContact person changed (no phone or email listed)
  • Clinical Centre of Vojvodina · Novi Sad, SerbiaContact person changed (no phone or email listed)
Oct 7, 2026
Show all 2 updates
  1. Nov 10, 2026
    Recruiting→Active, not recruiting
    11 sites removed
    Show 11 removed
    • Henry Ford St. John Hospital · Grosse Pointe Woods, United States
    • Dartmouth-Hitchcock Medical Center · Lebanon, United States
    • UPMC Hillman Cancer Center · Pittsburgh, United States
    • Grupo Oncoclínicas Pesquisa Clínica · São Paulo, Brazil
    • Hospital Paulistano, Centro de Pesquisa Clinica R. Martiniano de Carvalho · São Paulo, Brazil
    • UOC Oncoematologia, Ospedale Policlinico Federico II · Naples, Italy
    • CCAB Centro Clinico Academico Braga Associacao · Braga, Portugal
    • Instituto Portugues De Oncologia De Lisboa Francisco Gentil E.P.E. · Lisbon, Portugal
    • Instituto Portugues De Oncologia Do Porto Francisco Gentil E.P.E. · Porto, Portugal
    • Sao Joao University Hospital Center · Porto, Portugal
    • Unidade Local De Saude De Gaia/Espinho E.P.E. · Porto, Portugal
    + 2 other changes: verification date and contact details
  2. Oct 7, 2026
    6 sites changed recruiting status (4 now recruiting, 2 now withdrawn)
    Show 6 sites
    • UCLA Medical Center · Los Angeles, United StatesNot yet recruiting→Recruiting
    • University of Chicago · Chicago, United StatesNot yet recruiting→Recruiting
    • Henry Ford St. John Hospital · Grosse Pointe Woods, United StatesNot yet recruiting→Withdrawn
    • East Carolina University · Greenville, United StatesNot yet recruiting→Recruiting
    • Penn Medicine Lancaster General · Lancaster, United StatesNot yet recruiting→Recruiting
    • UPMC Hillman Cancer Center · Pittsburgh, United StatesNot yet recruiting→Withdrawn
    Site contacts Changed at 5 sites. See the sites
    Show 5 sites
    • Henry Ford St. John Hospital · Grosse Pointe Woods, United StatesContact removed (no phone or email listed)
    • UPMC Hillman Cancer Center · Pittsburgh, United StatesContact removed (no phone or email listed)
    • Barwon Health University Hospital Geelong Andrew Love Cancer Centre · Geelong, AustraliaContact person changed (no phone or email listed)
    • Calvary Mater Hospital · Newcastle, AustraliaContact person changed (no phone or email listed)
    • Clinical Centre of Vojvodina · Novi Sad, SerbiaContact person changed (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05243797
Lead sponsor
European Myeloma Network B.V.
Responsible party
Sponsor
First posted
Feb 17, 2022
Start date
Sep 8, 2022
Primary completion
Apr 2028 (estimated)
Completion
Apr 2032 (estimated)
Last update
Nov 10, 2026

Study contacts

Niels van de Donk, Professor
principal investigator · Amsterdam UMC, Vrije Universiteit Amsterdam
Elena Zamagni, Professor
principal investigator · IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli"

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Teclistamab · Lenalidomide

Start the discussion